How Preimplantation Genetic Testing Is Transforming IVF Success Rates

 Market Overview

The preimplantation genetic testing (PGT) market is experiencing substantial growth, driven by the increasing demand for genetic screening during in vitro fertilization (IVF) procedures. PGT involves analyzing embryos for genetic abnormalities before implantation, allowing clinicians to select healthy embryos for transfer, thereby increasing the chances of successful pregnancy and reducing the risk of genetic disorders in offspring.

The global preimplantation genetic testing market is projected to grow from USD 690.2 million in 2025 to USD 1,135.0 million by 2030, at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2030. This growth is attributed to several factors, including:

  • Increasing Awareness of Genetic Disorders: Growing awareness among couples about the risk of transmitting genetic disorders to their children is driving the demand for PGT.
  • Advancements in Technology: Technological advancements in PGT techniques, such as next-generation sequencing (NGS), have improved the accuracy and efficiency of genetic screening, making it more accessible and reliable.
  • Rising Demand for IVF Procedures: The increasing prevalence of infertility and the growing acceptance of IVF procedures are contributing to the growth of the PGT market.
  • Growing Disposable Incomes: Rising disposable incomes in developing countries are enabling more couples to afford PGT services.
  • Government Support: Supportive government policies and initiatives promoting reproductive health are also contributing to the growth of the PGT market.

Download PDF Brochure

Market Segmentation

The preimplantation genetic testing market can be segmented based on several factors, including:

By Test Type

  • Preimplantation Genetic Diagnosis (PGD): PGD is used to detect specific genetic mutations or chromosomal abnormalities in embryos when one or both parents are known carriers of a genetic disorder.
  • Preimplantation Genetic Screening (PGS): PGS is used to screen embryos for chromosomal abnormalities, such as aneuploidy (abnormal number of chromosomes), in couples who are not known carriers of a specific genetic disorder but are at risk of having a child with chromosomal abnormalities due to advanced maternal age or recurrent miscarriages.

By Technology

  • Next-Generation Sequencing (NGS): NGS is a high-throughput sequencing technology that allows for the simultaneous analysis of multiple genes or entire genomes, providing comprehensive genetic information about embryos.
  • Polymerase Chain Reaction (PCR): PCR is a molecular biology technique used to amplify specific DNA sequences, enabling the detection of genetic mutations or chromosomal abnormalities.
  • Fluorescence In Situ Hybridization (FISH): FISH is a cytogenetic technique used to detect and localize specific DNA sequences on chromosomes, allowing for the identification of chromosomal abnormalities.
  • Comparative Genomic Hybridization (CGH): CGH is a molecular cytogenetic technique used to detect chromosomal copy number variations, such as deletions or duplications.

By End User

  • Fertility Clinics: Fertility clinics are the primary end users of PGT services, offering genetic screening to couples undergoing IVF procedures.
  • Hospitals and Diagnostic Laboratories: Hospitals and diagnostic laboratories also offer PGT services, either independently or in collaboration with fertility clinics.
  • Research Institutes: Research institutes use PGT for research purposes, such as studying the genetic basis of infertility and developing new genetic screening techniques.

By Region

  • North America: North America is the largest market for PGT, driven by the high adoption rate of IVF procedures and the presence of advanced healthcare infrastructure.
  • Europe: Europe is the second-largest market for PGT, with a growing number of fertility clinics offering genetic screening services.
  • Asia Pacific: Asia Pacific is the fastest-growing market for PGT, driven by the increasing prevalence of infertility and the rising disposable incomes in developing countries.
  • Latin America: Latin America is an emerging market for PGT, with a growing number of couples seeking genetic screening services.
  • Middle East & Africa: The Middle East & Africa region is witnessing increasing adoption of PGT, driven by rising awareness of genetic disorders and government initiatives to improve reproductive health.

Key Market Players

The preimplantation genetic testing market is highly competitive, with several key players offering a range of PGT services and technologies. Some of the leading companies in the market include:

These companies are focused on developing innovative PGT technologies and expanding their service offerings to meet the growing demand for genetic screening during IVF procedures.

Market Trends

Several key trends are shaping the preimplantation genetic testing market:

  • Increasing Adoption of NGS Technology: NGS technology is becoming increasingly popular for PGT due to its high accuracy, comprehensive genetic information, and cost-effectiveness.
  • Growing Demand for Non-Invasive PGT (niPGT): niPGT involves analyzing cell-free DNA from the spent culture media of embryos, offering a non-invasive alternative to traditional PGT methods that require embryo biopsy.
  • Rising Focus on Single-Gene Disorder Testing: PGT is increasingly being used to screen embryos for specific single-gene disorders, such as cystic fibrosis, spinal muscular atrophy, and Huntington's disease.
  • Expanding Applications of PGT: PGT is being explored for new applications, such as selecting embryos for specific traits or characteristics, although ethical considerations surrounding these applications remain a subject of debate.

Request Sample Pages

Challenges and Opportunities

The preimplantation genetic testing market faces several challenges, including:

  • High Cost of PGT: The high cost of PGT can be a barrier to access for some couples, particularly in developing countries.
  • Ethical Concerns: Ethical concerns surrounding PGT, such as the potential for sex selection or the discarding of embryos with genetic abnormalities, need to be addressed.
  • Regulatory Issues: The regulatory landscape for PGT varies across different countries, creating challenges for companies operating in the global market.

Despite these challenges, the PGT market offers significant opportunities for growth:

  • Expanding Access to PGT: Efforts to reduce the cost of PGT and increase access to genetic screening services can drive market growth.
  • Developing New PGT Technologies: Continued innovation in PGT technologies, such as niPGT and advanced NGS platforms, can improve the accuracy and efficiency of genetic screening.
  • Addressing Ethical Concerns: Open and transparent discussions about the ethical implications of PGT can help to build public trust and acceptance of the technology.

Conclusion

The preimplantation genetic testing market is poised for significant growth in the coming years, driven by increasing awareness of genetic disorders, advancements in technology, and rising demand for IVF procedures. While challenges remain, the market offers significant opportunities for companies that can develop innovative PGT technologies and address the ethical concerns surrounding this rapidly evolving field. The projected CAGR of 10.5% from 2025 to 2030 underscores the strong growth potential of the PGT market, making it an attractive area for investment and innovation.

Comments

Post a Comment

Popular posts from this blog

Urology Devices Industry worth $48.6 billion by 2028

 The global urology devices market , valued at US$32.6 billion in 2022, is forecasted to grow at a robust CAGR of 7.3%, reaching US$34.1 billion in 2023 and an impressive US$48.6 billion by 2028. Investments by hospitals in procuring advanced instruments, expanding units, and establishing new centers are expected to boost the market for urology devices. Moreover, increased demand for MIS robotic systems is expected to increase in the coming years, which is expected to propel the market growth. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212 Browse in-depth TOC on “Urology Devices Market” 159 — Tables 44 — Figures 274 — Pages In 2022, the instruments segment held the largest share of the urology devices market by product segment. The urology devices market is segmented into instruments and consumables & accessories based on products. The instruments segment accounted for the largest share of the urology devices market in 2022....
Read more

Adhesion Barrier Industry worth $0.9 billion by 2028, with a CAGR of 7.4%

  The report   " Adhesion Barrier Market  by Product (Regenerated Cellulose, Hyaluronic Acid, PEG), Type (Film, Gel, Liquid), Procedure (Abdominal, Cardiovascular, Gynae, Neurology), End User (Hospitals, Clinics & ASC), Region- Global Forecast to 2028" , is valued at an estimated USD 0.7 billion in 2023 and is projected to reach USD 0.9 billion by 2028, at a CAGR of 7.4% during the forecast period. The main drivers of this market's expansion are the rising number of surgeries and sports-related injuries, an increasing elderly population, and a growing understanding by of the adhesion formation and health issues linked to adhesions. On the other hand, during the forecast period, it is projected that surgeons' resistance to using adhesion barriers will impede market expansion. Browse 207 market data Tables and 50 Figures spread through 238 Pages and in-depth TOC on  "Adhesion Barrier Market by Product (Regenerated Cellulose, Hyaluronic Acid, PEG), Type (F...
Read more

Healthcare Simulation Market worth $4.6 billion by 2028

Image
The global healthcare simulation market is projected to reach USD 4.6 billion by 2028 from USD 2.2 billion in 2023, at a high CAGR of 15.7% during the forecast period. The market's expansion is fuelled by an advancement in technology, such as high-fidelity manikins and virtual reality that have enhanced the realism and effectiveness of simulation training, for instance, high-fidelity simulators like Apollo (by Elevate Healthcare (formerly CAE)) and Nursing Anne Simulator (by Laerdal Medical) accelerates learning, reduces training time, and improves debriefing with automated patient responses; the growing complexity of modern medical procedures which requires training solutions offered by simulation. Further, the increasing number of medical schools is also propelling this market. For instance, according to Ministry of Health and Family Welfare, in India, the number of medical colleges has risen by 82%, from 387 before 2014 to 706 for the year 2024. Healthcare Simulation Market – G...
Read more